What is Aadi Bioscience?
Aadi Bioscience operates at the intersection of oncology and precision pharmacology. The company is dedicated to developing transformational therapies for patients with mTOR pathway driver alterations, specifically targeting TSC1 or TSC2 gene mutations. By addressing the limitations of existing mTOR inhibitors—such as safety profiles, drug delivery challenges, and site-specific targeting—Aadi Bioscience is carving out a specialized niche in the biopharmaceutical landscape. Their market position is defined by a rigorous scientific approach to solving complex therapeutic problems, aiming to improve clinical outcomes where conventional treatments have historically failed.
How much funding has Aadi Bioscience raised?
Aadi Bioscience has raised a total of $195.7M across 4 funding rounds:
Series A
$23M
Debt
$150K
Share Placement
$72.5M
Share Placement
$100M
Series A (2017): $23M with participation from Vivo Capital, Decheng Capital, Helsinn Investment Fund, Hermed Capital, and Celgene Corporation
Debt (2020): $150K led by PPP
Share Placement (2022): $72.5M, investors not publicly disclosed
Share Placement (2025): $100M, investors not publicly disclosed
Key Investors in Aadi Bioscience
Vivo Capital
A global healthcare investment firm founded in 1996 that manages private and public equity, as well as venture capital, with a focus on long-term medical innovation.
Decheng Capital
A global investment firm specializing in early-stage life science and growth-stage healthcare companies, leveraging over $2.1 billion in capital to support revolutionary medical technologies.
Helsinn Investment Fund
A Luxembourg-based fund owned by the Helsinn Group, focused on early-stage investments in cancer therapeutics, diagnostics, and supportive care to address high unmet patient needs.
What's next for Aadi Bioscience?
With the recent influx of capital, Aadi Bioscience is well-positioned to scale its clinical operations and deepen its research into mTOR-driven malignancies. The strategic focus will likely shift toward optimizing the commercialization pathway for its lead candidates while maintaining a lean, high-impact R&D structure. Investors are closely monitoring the company's ability to translate its precision oncology platform into tangible patient benefits, which will be the primary driver for future valuation growth. As the firm matures, the integration of advanced diagnostic tools and expanded clinical trial sites will be essential to maintaining its competitive edge in the rapidly evolving oncology sector.
See full Aadi Bioscience company page
